Pharmacokinetics and Safety of Duloxetine, a Dual‐Serotonin and Norepinephrine Reuptake Inhibitor
The DOI matches its Crossref record.
Abstract
The pharmacokinetics and safety of duloxetine were evaluated in a single‐blind, placebo‐controlled, escalating multiple‐dose study in 12 healthy male subjects. In the treatment group (n = 8), duloxetine was administered orally at a starting dose of 20 mg twice daily (bid) and escalated at weekly intervals to 30 mg bid, then to 40 mg bid. The observed plasma concentration‐time data at all three dose levels were adequately described by a one‐compartment model with a first‐order absorption rate constant. The mean oral clearance, apparent volume of distribution, and half‐life values were 114 L/h (range: 44 to 218 L/h), 1943 L (range: 803 to 3531 L), and 12.5 h (range: 9.2 to 19.1 h), respectively. Somnolence, nausea, and dry mouth were observed following the initial dose, but they resolved with continuing drug administration. Duloxetine was not associated with clinically significant changes in blood pressure (BP) or heart rate (HR) measured in the standing position. However, in recumbent position, small increases in systolic (≤ 9 mmHg) and diastolic (≤ 5 mmHg) BP and small decreases in HR (≤ 6 beats/min) were observed. Abrupt discontinuation of duloxetine was associated with a small increase in mean HR (≤ 12beats/min). In 3 subjects, abrupt discontinuation was also associated with transient sleep disturbance. No clinically important changes in electrocardiograms, cardiac intervals, clinical laboratory tests, and neurological functions were observed. These results indicate that duloxetine exhibits linear pharmacokinetics with respect to dose and duration of treatment and that a multiple oral dose regimen starting at 20 mg bid and gradually escalating up to 40 mg bid was generally well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain
Wernicke, J. F., Pritchett, Y. L., D’Souza, D. N., Waninger, A., Tran, P., Iyengar, S., & Raskin, J. (2006) · Neurology · doi:10.1212/01.wnl.0000240225.04000.1a · Cited by 510
Management of Overactive Bladder
Ouslander, J. G. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032662 · Cited by 411
Vincent, S., Bieck, P. R., Garland, E. M., Loghin, C., Bymaster, F. P., Black, B. K., Gonzales, C., Potter, W. Z., & Robertson, D. (2004) · Circulation · doi:10.1161/01.cir.0000130847.18666.39 · Cited by 102
Abanades, S., van der Aart, J., Barletta, J. A., Marzano, C., Searle, G. E., Salinas, C. A., Ahmad, J. J., Reiley, R. R., Pampols-Maso, S., Zamuner, S., et al. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.175 · Cited by 61
Duloxetine for the treatment of fibromyalgia
Wright, C. L., Mist, S. D., Ross, R. L., & Jones, K. D. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.64 · Cited by 43
Metadata
- Authors
- Sharma, A., Goldberg, M. J., & Cerimele, B. J.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2000-02
- Volume
- 40
- Issue
- 2
- Pages
- 161-167
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2072772870
- Cited by
- 145
- References
- 0
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics and Safety of Duloxetine, a Dual‐Serotonin and Norepinephrine Reuptake Inhibitor. https://app.cochat.ai/papers/10.1177/00912700022008810
- The paper
- Sharma, A., Goldberg, M. J., & Cerimele, B. J. (2000). Pharmacokinetics and Safety of Duloxetine, a Dual‐Serotonin and Norepinephrine Reuptake Inhibitor. The Journal of Clinical Pharmacology. https://doi.org/10.1177/00912700022008810
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.